|
ABC-07 |
Addition of stereotactic radiotherapy to systemic chemotherapy in locally advanced biliary tract cancers |
Dr Thankamma Ajithkumar |
31 Aug 2023 |
5 Apr 2017 |
Liver & Bile Duct |
|
Add-Aspirin Trial |
A phase III, double blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours |
Dr Luke Hughes-Davies |
11 Dec 2021 |
21 Dec 2015 |
Breast, Colorectal, Oesophageal, Prostate |
|
ADSCaN |
A Randomised Phase II study of Accelerated, Dose escalated, Sequential Chemo-radiotherapy in Non-small Cell Lung Cancer |
Dr David Gilligan |
31 Dec 2021 |
23 Nov 2017 |
Lung |
|
ALF Research Study |
Research into Altered Lymphocyte Function in Health and Disease |
Dr Kate Fife |
31 Dec 2022 |
9 Nov 2017 |
Skin & melanoma |
|
Amadeus |
A Double-Blind, Phase III, Randomised Study to Compare the Efficacy and Safety of Oral Azacitidine (CC-486) Versus Placebo in Subjects with Acute Myeloid Leukaemia or Myelodysplastic Syndromes as Maintenance after Allogeneic Haematopoietic Stem Cell Transplantation |
Dr Charles Crawley |
31 Dec 2022 |
19 Dec 2019 |
Haematological |
|
BEAT-meso |
A multicentre randomised phase III trial comparing atezolizumab plus bevacizumab and standard chemotherapy versus bevacizumab and standard chemotherapy as first-line treatment for advanced malignant pleural mesothelioma |
Dr David Gilligan |
15 Jan 2025 |
5 Sep 2019 |
Lung |
|
Best-Of |
Phase III study assessing the "Best-Of" radiotherapy compared to the "Best-Of" surgery (trans-oral surgery (TOS) in patients with T1-T2, N0 oropharyngeal carcinoma |
Dr Ekpemi Irune |
1 Jan 2026 |
17 Nov 2020 |
Head & neck |
|
CHIRON |
An Open-Label, Multi-Centre Phase I/IIa Study Evaluating the Safety and Clinical Activity of Neoantigen Reactive T cells in Patients with Advanced Non-Small Cell Lung Cancer |
Dr Gary Doherty |
31 Oct 2021 |
21 Jan 2020 |
Lung |
|
CompARE Trial |
Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer |
Dr Rashmi Jadon |
31 Jan 2026 |
5 Mar 2019 |
Head & neck |
|
COSI |
An International Randomised Clinical Trial of Therapeutic Interventions with the Potential to Improve Outcome in Adults with Acute Myeloid Leukaemia and High Risk Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation |
Dr Charles Crawley |
1 Apr 2025 |
9 Sep 2020 |
Haematological |
|
COSMIC-313 |
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk |
Dr Kate Fife |
31 Dec 2025 |
6 Dec 2019 |
Kidney |
|
Dante |
A randomised phase III trial to evaluate the duration of anti-PD1 monoclonal antibody treatment in patients with metastatic melanoma |
Dr Pippa Corrie |
31 Mar 2023 |
21 Sep 2018 |
Skin & melanoma |
|
DIG (Diffusion imaging in gliomas) |
Quantitative diffusion imaging for early treatment response and progression evaluation in adult high grade gliomas; a multicentre study |
Dr Tomasz Matys |
31 Dec 2022 |
13 Jul 2018 |
Brain and CNS |
|
DS8201-A-U205 (Daiichi) |
A phase 2, open-label, single-arm trial of Trastuzumab Deruxtecan (DS-8201A) in HER2-positive, unresectable ormetastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma subjects who have progressed on or after a Trastuzumab containing regime |
Dr Lizzie Smyth |
1 Apr 2022 |
13 Dec 2019 |
Oesophageal |
|
EMBRACE-II |
Image guided intensity modulated External beam radiochemotherapy and MRI based adaptive BRAchytherapy in locally advanced CErvical cancer |
Dr Li Tee Tan |
30 Jun 2024 |
7 Nov 2017 |
Gynaecological |
|
FIGHT 302 |
A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement |
Dr Bristi Basu |
18 Oct 2021 |
4 Jul 2019 |
Liver & Bile Duct |
|
FLAURA-2 |
A phase III, open-label, randomized study of osimertinib with or without platinum plus pemetrexed chemotherapy, as first-line treatment in patients with epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic non-small cell lung cancer (FLAURA-2) |
Dr Gary Doherty |
23 Mar 2026 |
25 Sep 2020 |
Lung |
|
Hamlet.rt (H&N) |
Hamlet.rt - Heuristics, Algorithms and Machine Learning: Evaluation & Testing in Radiation Therapy |
Dr Raj Jena |
31 Oct 2021 |
24 Oct 2019 |
Head & neck |
|
Hamlet.rt (Prostate) |
Hamlet.rt - Heuristics, Algorithms and Machine Learning: Evaluation & Testing in Radiation Therapy |
Dr Raj Jena |
31 Oct 2021 |
24 Oct 2019 |
Prostate |
|
ICONIC |
Improving outcomes through collaboration in osteosarcoma |
Dr Han Wong |
30 Sep 2022 |
13 Dec 2019 |
Sarcoma |
|
KEYNOTE-641 |
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
Dr Danish Mazhar |
30 Apr 2024 |
8 Oct 2019 |
Prostate |
|
LEAP-006 |
A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) with or without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants with Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006) |
Dr Gary Doherty |
30 Sep 2024 |
18 Sep 2020 |
Lung |
|
LI-1 |
Leukaemia Lymphoma Research and NCRI Working Group Pick a Winner Programme (LI1) Trial |
Dr Jenny Craig |
31 Dec 2021 |
17 Feb 2014 |
Haematological |
|
MelResist |
Investigating resistance to gene-targeted melanoma therapies |
Dr Pippa Corrie |
31 Dec 2021 |
3 Dec 2011 |
Skin & melanoma |
|
MITRE |
Microbiome Immunotherapy Toxicity and Response Evaluation (MITRE) An observational study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy |
Dr Pippa Corrie |
31 Dec 2024 |
30 Mar 2021 |
Kidney, Lung, Skin & melanoma |
|
MONITOR |
Multi-centre Observational study of maintenance Nirparib in Treatment of Ovarian CanceR: UK routine clinical practice experience |
Dr Joo Ern Ang |
3 Jan 2022 |
14 Oct 2020 |
Gynaecological |
|
MyeChild 01 |
International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination with Induction Chemotherapy |
Dr Michael Gattens |
1 Nov 2021 |
31 Oct 2016 |
Haematological |
|
Myeloma XII |
A phase III study to determine the role of ixazomib as an Augmented Conditioning therapy in salvage autologous stem |
Dr Charles Crawley |
31 Dec 2021 |
22 May 2017 |
Haematological |
|
OPTIMA |
Optimal Personalised Treatment of early breast cancer using Multiparameter Analysis |
Dr Luke Hughes-Davies |
31 Oct 2021 |
25 Oct 2012 |
Breast |
|
PACE-C |
International randomised study of prostatectomy vs stereotactic body radiotherapy (SBRT) and conventional radiotherapy vs SBRT for organ-confined prostate cancer |
Dr Alex Martin |
26 Apr 2026 |
5 Feb 2020 |
Prostate |
|
PATHOS |
A Phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV)-positive oropharyngeal cancer |
Dr Ekpemi Irune |
31 Dec 2021 |
16 Jun 2017 |
Head & neck |
|
Pharmacyclics PCYC 1141 (Bruton's Tyrosine Kinase Inhibitor, Treatment for Follicular Lymphoma) |
A Multicentre, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma |
Dr George Follows |
16 Mar 2025 |
27 Jul 2018 |
Haematological |
|
PLATO |
PersonaLising Anal cancer radioTherapy dOse |
Dr Catherine Jephcott |
31 Dec 2022 |
22 Mar 2017 |
Colorectal |
|
POPS |
A randomised phase II trial assessing Post-Operative use of ProSpare, a rectal obturator in prostate cancer radiotherapy |
Dr Yvonne Rimmer |
31 Dec 2021 |
4 Jul 2017 |
Prostate |
|
PRECISION-Panc |
Advancing personalised medicine treatment strategies for pancreatic cancer |
Dr Bristi Basu |
28 Feb 2023 |
25 Apr 2018 |
Pancreatic |
|
PRIMETIME |
Post-operative avoidance of radiotherapy in minimal risk women: patient selection using biomarkers |
Dr Charlotte Coles |
31 Dec 2021 |
18 May 2017 |
Breast |
|
PRIMUS-001 |
An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation |
Dr Pippa Corrie |
30 Apr 2022 |
10 May 2018 |
Pancreatic |
|
Quality of Life After Bladder Cancer (Q-ABC) |
A comparison of patient related outcomes following radical surgery and radiotherapy |
Dr Yvonne Rimmer |
1 Mar 2022 |
23 Oct 2018 |
Bladder |
|
RAMPART |
Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART): An international investigator-led phase III multi-arm multi-stage multi-centre randomised-controlled platform trial of adjuvant therapy in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse |
Dr Sarah Welsh |
31 Dec 2023 |
20 Jul 2018 |
Kidney |
|
rEECur |
International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma |
Dr Han Wong |
30 Sep 2022 |
5 May 2016 |
Sarcoma |
|
ROAM |
Radiation versus observation following surgical resection of atypical meningioma: A randomised controlled trial |
Dr Sarah Jefferies |
30 Apr 2025 |
17 Nov 2016 |
Brain and CNS |
|
Ruby |
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-Paclitaxel versus Placebo plus Carboplatin-Paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer |
Dr Joo Ern Ang |
18 May 2023 |
26 Nov 2020 |
Gynaecological |
|
SARON |
Stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer. A randomised phase III trial |
Dr Alex Martin |
4 Jul 2023 |
9 Aug 2017 |
Lung |
|
SKYSCRAPER-07 |
A phase III randomised , double-blind, placebo-controlled study of Atezolizumab with or without Tiragolumab (anti-tigit antibody) in patients with locally advanced esophageal squamous cell carcinoma |
Dr Lizzie Smyth |
31 Dec 2025 |
17 Nov 2020 |
Oesophageal |
|
SPECTA (EORTC 1553) |
Screening cancer patients for efficient clinical trial access |
Dr Sarah Welsh |
31 Dec 2021 |
1 Aug 2018 |
Kidney |
|
SPECTA (EORTC 1553) (Sarcoma) |
Screening cancer patients for efficient clinical trial access |
Dr Helen Hatcher |
31 Dec 2021 |
1 Aug 2018 |
Sarcoma |
|
SPECTA (EORTC 1553) (Skin & Melanoma) |
Screening cancer patients for efficient clinical trial access |
Dr Kate Fife |
31 Dec 2021 |
1 Aug 2018 |
Skin & melanoma |
|
Spotlight |
A Phase 3, Global, Multi-Centre, Double-Blind, Randomised, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma |
Dr Lizzie Smyth |
14 Feb 2022 |
4 Sep 2020 |
Oesophageal |
|
SPRING |
Seizure prophylaxis in Glioma |
Mr Stephen Price |
31 May 2023 |
11 Dec 2019 |
Brain and CNS |
|
Target Fal01 |
Translational Analysis and Research in Gynaecological Epithelial Tissues - Fallopian Tubes |
Dr Filipe Correia Martins |
30 Nov 2021 |
11 Jan 2019 |
Gynaecological |
|
WIRE |
Window-of-opportunity clinical trials platform for evaluation of novel treatment strategies in renal cell cancer |
Dr Sarah Welsh |
6 Jun 2023 |
22 Jul 2020 |
Kidney |
